AMALY — SHARIAH COMPLIANCE REPORT
==================================
Symbol: IMUX
Report Date: 2026-04-29
Full Report: https://amaly.io/stock/IMUX

EXECUTIVE SUMMARY
------------------
Compliance Status: NON_COMPLIANT
Quality Rating: B
Description: Immunic, Inc. (IMUX) is a clinical-stage biopharmaceutical company focused on developing oral therapies for chronic inflammatory diseases. The analysis indicates strong performance in debt and liquidity ratios, with no evident non-compliant business activities. However, insufficient data on interest and non-permissible income leads to some under-review statuses. Overall, while financial screens are favorable, the lack of index inclusion results in a non-compliant classification. Investors should monitor upcoming financial disclosures for full verification.

Primary Compliance Concerns:
- Insufficient data for interest income ratio (0.00%, threshold: 5%)
- Insufficient data for non-permissible income ratio (0.00%, threshold: 5%)
- Limited historical data for trend analysis

Purification Requirement: 0.00%
Index Inclusion: Not included in any of the four major Shariah-compliant indices

KEY FINANCIAL METRICS
----------------------
Debt Ratio: 0.0%
Liquidity Ratio: 0.0%
Interest Income Ratio: 0.0%
Purification Required: 0.00%

INDEX INCLUSION STATUS
-----------------------
S&P Shariah: EXCLUDED
MSCI Islamic: EXCLUDED
DJIM: EXCLUDED
FTSE Shariah: EXCLUDED
Total: 0 of 4
Last Verified: Unknown

REPORTING PERIOD
-----------------
Latest Annual Report: FY 2025
Latest Quarterly Data: Q4 2025
Trend Period: FY 2020 to FY 2025
Data Retrieved: 2026-02-14T12:00:00Z

---
Full interactive report: https://amaly.io/stock/IMUX
Provided by Amaly (https://amaly.io) — Shariah Compliant Stock Screener
Disclaimer: This data is for informational purposes only and does not constitute financial or religious advice.